|
Market Closed -
Nasdaq
04:00:00 2026-05-15 pm EDT
|
5-day change
|
1st Jan Change
|
|
1.280 USD
|
-1.54%
|
 |
-22.66%
|
-7.25%
|
|
May. 14 |
Neuronetics and Ant Neuro Enter Strategic Collaboration to Integrate Neuronavigation with Neurostar Tms Treatment
|
CI
| |
May. 05 |
Neuronetics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026
|
CI
| |
May. 05 |
Neuronetics, Inc. Provides Earnings Guidance for the Second Quarter and Full Year 2026
|
CI
| |
Apr. 13 |
Neuronetics, Inc. Highlights Optum/UHC/UBH TMS Policy Expansion Enabling PMHNPs To Deliver NeuroStar Therapy Across 26 States And Washington D.C
|
CI
| |
Apr. 06 |
Jorey Chernett Calls for Immediate and Comprehensive Review of Strategic Alternatives at Neuronetics
|
CI
| |
Mar. 17 |
Neuronetics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025
|
CI
| |
Mar. 17 |
Neuronetics, Inc. Provides Earnings Guidance for the First Quarter and Full Year 2026
|
CI
| |
Nov. 04 |
Neuronetics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025
|
CI
| |
Nov. 04 |
Neuronetics, Inc. Provides Revenue Guidance for the Fourth Quarter 2025
|
CI
| |
Nov. 04 |
Neuronetics, Inc. Revises Earnings Guidance for the Full Year 2025
|
CI
| |
Nov. 04 |
Neuronetics Q3 revenue misses estimates
|
RE
| |
25-10-30 |
Neuronetics Announces Three-Year Exclusive Partnership with Elite DNA Behavioral Health to Expand Neurostar Access and Operational Excellence
|
CI
| |
25-08-05 |
Neuronetics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025
|
CI
| |
25-08-05 |
Healthcare firm Neuronetics Q2 revenue beats estimates
|
RE
| |
25-08-05 |
Neuronetics, Inc. Provides Earnings Guidance for the Third Quarter and Full Year Ending December 31, 2025
|
CI
| |
25-07-15 |
Neuronetics appoints new chief financial officer
|
RE
| |
25-05-06 |
Neuronetics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025
|
CI
| |
25-05-06 |
Neuronetics, Inc. Revises Earnings Guidance for the Full Year 2025
|
CI
| |
25-05-06 |
Neuronetics, Inc. Provides Earnings Guidance for the Second Quarter of 2025
|
CI
| |
25-03-27 |
Neuronetics Some Non-Cash Revisions Made To Financial Statements Related To Co's Acquisition Of Greenbrook Tms & Shares Outstanding In Q4
|
RE
| |
25-03-04 |
Neuronetics, Inc. Provides Earnings Guidance for the First Quarter and Full Year 2025
|
CI
| |
25-03-04 |
Neuronetics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2024
|
CI
| |
25-02-07 |
Neuronetics Seeks Acquisitions
|
CI
| |
25-02-07 |
Neuronetics Prices Eight Million Share Offering at $2.25 Per Share
|
MT
| |
25-01-29 |
Neuronetics, Inc. Unveils Two Significant Publications on TMS Therapy for Depression
|
CI
|
No results for this search Select your edition All financial news and data tailored to specific country editions | 
